NCT04102436
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on first-line treatments
Exclusions: Patients with more than 3 brain metastases
https://ClinicalTrials.gov/show/NCT04102436